SAVANNAH, Ga., Aug 11, 2008 (BUSINESS WIRE) -- Health Discovery Corporation
("HDC") (OTCBB: HDVY) today announced that HDC's new gene-based molecular
diagnostic test for prostate cancer which has now successfully completed its
Phase III double-blind clinical trial and is now ready for commercialization,
will be presented at the upcoming Biomarker Discovery Europe 2008 conference in
Dublin, Ireland on October 2-3. The new prostate cancer test will be performed
at Clarient's Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30%
royalty on each test performed.
Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corporation, was
invited to participate as a Distinguished Presenter on the Faculty of the
Biomarker Discovery Europe 2008 Summit. Other Distinguished Presenters at the
Conference include Senior Executives from companies such GlaxoSmithKline,
Hoffmann-La Roche, AstraZeneca, Celgene, Abbott Laboratories, B.D. Diagnostics
and others, as well as, speakers from academia and the FDA. In addition, Dr.
Herb Fritsche, Professor of Laboratory Medicine and Chief of the Clinical
Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in
Houston, Texas and Chairman of HDC's Science Team will be a Keynote Speaker at
the Conference.
Dr. Barnhill will present the results from Phase I, Phase II and Phase III
double-blind clinical validation studies now completed with prostate tissues
obtained from multiple sites, including those tested in collaboration with MD
Anderson Cancer Center which demonstrated a very high success rate for
identifying the presence of Grade 3 or higher prostate cancer cells (clinically
significant cancer), as well as, normal and BPH (benign prostatic hyperplasia)
cells. His presentation will emphasize that to date, 322 prostate tissues have
been tested - and that the combined results of the recently completed
double-blind clinical validation studies demonstrated on the new gene-based
molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for
correctly identifying the presence of Grade 3 or higher prostate cancer cells,
and a Specificity of 97% for correctly identifying non-cancer cells (normal and
BPH), representing an overall test accuracy of 93%.
"I am honored to be asked to join the list of Distinguished Presenters at this
very important medical conference and look forward to discussing the successful
results of our recently completed clinical trials for the HDC molecular
diagnostic test for prostate cancer with the distinguished members of the
Faculty, as well as, all of the participants who sign up to attend the
conference," stated Stephen D. Barnhill, M.D., Chairman and CEO of Health
Discovery Corporation. "I am pleased to have the opportunity to introduce HDC's
new gene-based prostate cancer test to the market like similar molecular
diagnostic tests based on unique gene expression profiles such as OncotypeDX
from Genomic Health, Inc. (NasdaqGM:GHDX) and MammaPrint from Agendia."
About Health Discovery Corporation
Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned
in the field of pattern recognition technology. Through the application of its
patent protected technology, HDC is a leader in SVM-based molecular diagnostic
and prognostic test development in genomics and proteomics, as well as, digital
image analysis in pathology and radiology. The Company's SVM and FGM pattern
recognition tools have significant application potential in other sizable
commercial markets such as oil exploration, financial markets, Internet search
and spam, homeland security, and other areas where analysis of large volumes of
complex data is required. www.healthdiscoverycorp.com.
This news release contains "forward-looking statements" within the meaning of
Section 27a of the Securities Acts of 1933 and Section 21E of the Securities
Exchange Act of 1934. Although the management team of HDC believes that the
expectations reflected in such forward-looking statements are reasonable, they
can give no assurance that such expectations will prove correct.
SOURCE: Health Discovery Corporation
CONTACT: Health Discovery Corporation
Stephen D. Barnhill, MD, CEO, 912-443-1987
sbarnhill@healthdiscoverycorp.com
www.healthdiscoverycorp.com
Copyright Business Wire 2008
**********************************************************************
As of Thursday, 08-07-2008 23:59, the latest Comtex SmarTrend® Alert,
an automated pattern recognition system, indicated an UPTREND on
05-02-2008 for ABT @ $54.00.
For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com
SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright © 2004-2008 Comtex News Network, Inc. All rights reserved.